外周血单个核细胞治疗糖尿病患者下肢缺血:单中心经验
单中心纳入50例糖尿病合并严重下肢缺血患者,全部接受外周血单个核细胞(PBMNCs)治疗,其中32例联合腔内血运重建(辅助治疗组),18例无法或血运重建失败者仅行PBMNCs治疗。中位随访10个月,两组经皮氧分压(TcPO2)均改善、视觉模拟量表(VAS)评分均下降,大截肢率分别为9.4%和16.7%(P=0.6)。
要点
- 辅助治疗组TcPO2由25±9.2 mmHg升至45.6±19.1 mmHg,VAS由8.6±2.1降至3.8±3.5。
- PBMNCs治疗组TcPO2由16.2±7.2 mmHg升至23.5±8.4 mmHg,VAS由9±1.1降至4.1±3.3。
- 大截肢辅助治疗组3例(9.4%)vs PBMNCs治疗组3例(16.7%),P=0.6。
核心结论
- 作者认为PBMNCs细胞治疗对不适合血运重建的患者起决定性作用。
- 作者认为对糖尿病合并严重下肢缺血及愈合抵抗性溃疡患者,辅助PBMNCs治疗可能代表一种有效的治疗选择。
研究设计与样本
- 单中心研究,纳入50例糖尿病合并严重下肢缺血患者,全部接受PBMNCs治疗。
- 32例接受PBMNCs联合腔内血运重建(辅助治疗组);18例被认为无法血运重建或血运重建失败,仅行PBMNCs治疗(PBMNCs治疗组)。
- 中位随访期为10个月。
主要发现
- 辅助治疗组平均TcPO2由25±9.2 mmHg改善至45.6±19.1 mmHg(P<0.001),VAS评分均值由8.6±2.1降至3.8±3.5(P=0.001)。
- PBMNCs治疗组平均TcPO2由16.2±7.2 mmHg改善至23.5±8.4 mmHg(P<0.001),VAS评分均值由9±1.1降至4.1±3.3(P=0.001)。
- 大截肢在辅助治疗组观察3例(9.4%),在PBMNCs治疗组观察3例(16.7%)(P=0.6)。
临床怎么用
- 作者认为PBMNCs细胞治疗对不适合血运重建的患者起决定性作用。
- 作者认为对糖尿病合并严重下肢缺血及愈合抵抗性溃疡患者,辅助PBMNCs治疗可能代表一种有效的治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this study is to analyze the effects of peripheral blood mononuclear cells (PBMNCs) therapy in diabetic patients with critical limb ischemia (CLI), with particular regard to its application, as adjuvant therapy in patients underwent endovascular revascularization. METHODS: Fifty diabetic patients affected by CLI were enrolled. All patients underwent PBMNCs therapy. Thirty-two patients underwent PBMNCs therapy associated with endovascular revascularization (adjuvant therapy group). In 18 patients, who were considered nonrevascularizable or underwent unsuccessful revascularization, regenerative therapy with PBMNCs was performed as the therapeutic choice (PBMNCs therapy group). RESULTS: The median follow-up period was 10 months. The baseline and end point results in adjuvant group were as follows. The mean transcutaneous partial pressure of oxygen (TcPO2) improved from 25 ± 9.2 mmHg to 45.6 ± 19.1 mmHg (P < 0.001), and visual analogue scale (VAS) score means decreased from 8.6 ± 2.1 to 3.8 ± 3.5 (P = 0.001). In PBMNCs therapy group, the mean TcPO2 improved from 16.2 ± 7.2 mmHg to 23.5 ± 8.4 mmHg (P < 0.001), and VAS score means decreased from 9 ± 1.1 to 4.1 ± 3.3 (P = 0.001). Major amputation was observed in 3 cases (9.4%), both in adjuvant therapy group and in PBMNCs therapy one (16.7%) (P = 0.6). CONCLUSIONS: The role of cellular therapy with PBMNCs is decisive in the patients that are not susceptible to revascularization. In diabetic patients with CLI and healing resistant ulcers, the adjuvant PBMNCs therapy could represent a valid therapeutic option.
引用
- Persiani F, Paolini A, Camilli D, et al. Peripheral Blood Mononuclear Cells Therapy for Treatment of Lower Limb Ischemia in Diabetic Patients: A Single-Center Experience. Ann Vasc Surg. 2018. PMID: 30053546. doi:10.1016/j.avsg.2018.05.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。